Renal Cell Carcinoma
News
Cabozantinib improves overall survival in renal cell carcinoma
Key clinical point: Cabozantinib significantly improved overall survival, compared with everolimus in patients with renal cell carcinoma. Major...
News
SU2C announces researcher-industry collaboration on immunotherapy
News
Immune agonist, checkpoint inhibitor combo shows good tolerability
Combining two immunotherapies, one inhibiting immune suppression and the other stimulating immune activation, is well tolerated and shows activity...
News
FDA grants accelerated approval to nivolumab for Hodgkin lymphoma
News
FDA approves lenvatinib for advanced renal cell carcinoma
News
Immune checkpoint inhibitors have antitumor activity in gastric, esophageal cancers
Key clinical point: Nivolumab and pembrolizumab appear active and well tolerated in patients with previously treated esophagogastric cancers....
News
Individualized approach improves surveillance after renal cell carcinoma resection
Key clinical point: An individualized approach to surveillance after surgical resection in patients with renal cell carcinoma may provide better...
News
Nivolumab benefits patients with previously treated renal cell carcinoma
Key clinical point: A majority of previously treated patients with renal cell carcinoma benefited from nivolumab. Major finding: At a median 45-...